Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of a notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of GSK American Depositary Shares (ADSs) on January 18, 2013, at a price of $43.94 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports on the notification of the ADS allocation increase in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on January 18, 2013.
- Share Price: The ADS price used for the revaluation was $43.94.
- Individual Allocations:
- Dr M M Slaoui: 19 ADSs
- Dr K Slaoui: 5 ADSs
- Mr W C Louv: 9 ADSs
- Connected Persons: No connected persons were listed with ADS allocations in this specific notification.